Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Fulcrum Therapeutics, Inc. FULC

Fulcrum Therapeutics said Esther Rajavelu has resigned from her position as chief financial officer and treasurer effective April 21, 2023. The company’s stock has a 52-week low of $2.25 .
RSI Value: 25.75
FULC Price Action: Shares of Fulcrum Therapeutics fell 9.6% to close at $2.26 on Wednesday.

Alpha Teknova, Inc. TKNO

Alpha Teknova posted a narrower-than-expected quarterly loss. “We achieved our operational objectives in 2022, positioning the company for significant and sustainable long-term growth,” said Stephen Gunstream, President and Chief Executive Officer of Teknova. The company’s stock has a 52-week low of $2.30.
RSI Value: 29.22
TKNO Price Action: Shares of Alpha Teknova fell 7.6% to close at $2.32 on Wednesday.

bluebird bio, Inc. BLUE

Bluebird Bio signaled a delay in its sickle cell disease drug application to the FDA in its Q4 earnings release. The company’s stock has a 52-week low of $2.78.
RSI Value: 29.91
BLUE Price Action: Shares of bluebird bio fell 6.7% to close at $2.79 on Wednesday.

Cara Therapeutics, Inc. CARA

Cara Therapeutics reported worse-than-expected Q4 EPS and sales results. “As the U.S. launch of KORSUVA® (difelikefalin) injection continues to progress, we are encouraged by the positive feedback from providers and patients. During the fourth quarter of 2022, we saw both new clinic and repeat orders driving product uptake, bolstering our confidence in KORSUVA’s long-term potential,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. The company’s 52-week low is $4.25.
RSI Value: 23.55
CARA Price Action: Shares of Cara Therapeutics fell 4.3% to close at $4.27 on Wednesday.

Replimune Group, Inc. REPL

Replimune reported Q3 financial results and issued corporate update. “We ended 2022 with a data update from our registration directed IGNYTE cohort of RP1 in anti-PD1 failed melanoma that demonstrated impressive and clinically meaningful activity in a patient population of major unmet need and with limited treatment options,” said Philip Astley-Sparke CEO of Replimune. The company has a 52-week low of $13.05.
RSI Value: 29.99
REPL Price Action: Shares of Replimune Group fell 2.4% to close at $15.65 on Wednesday.